Clinical Trial Update: Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluates the efficacy and safety of Actonel (risedronate) for patients with postmenopausal osteoporosis after discontinuation of denosumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Actonel (risedronate)

Snippet

Sponsor: Dong-A ST Co., Ltd. | Conditions: Postmenopausal Osteoporosis | Phase 4 | Status: COMPLETED